Tinjauan  Ketepatan  Dosis  Kemoterapi  Injeksi Kombinasi  Pada  Pasien  Kanker  Payudara One Day Care Di  RSUD Dr.  Achmad  Mochtar  Bukittinggi

Refi Khairah; Deswati Deswati; Khairil Armal

doi:10.1111/alsyifa.v1i2.223

Penulis

Refi Khairah Universitas Mohammad Natsir Bukittinggi, Indonesia
Deswati Deswati Universitas Mohammad Natsir Bukittinggi, Indonesia
Khairil Armal Universitas Mohammad Natsir Bukittinggi, Indonesia

DOI:

https://doi.org/10.1111/alsyifa.v1i2.223

Kata Kunci:

Ketepatan Dosis, Kemoterapi Injeksi Kombinasi, Kanker Payudara

Abstrak

Penelitian ini dilatarbelakangi oleh pentingnya ketepatan dosis kemoterapi untuk menjamin efektivitas terapi dan meminimalkan toksisitas pada pasien kanker payudara serta belum adanya penelitian serupa di RSUD Dr. Achmad Mochtar Bukittinggi. Tujuan penelitian untuk meninjau ketepatan dosis kemoterapi injeksi kombinasi dan mengidentifikasi efek samping pada pasien kanker payudara One Day Care. Penelitian dilakukan secara mixed methods dengan desain deskriptif melalui observasi dokumen dan pencatatan efek samping. Populasi penelitian adalah seluruh pasien kanker payudara yang menjalani kemoterapi injeksi kombinasi dengan teknik total sampling sebanyak 51 pasien. Instrumen penelitian menggunakan checklist kesesuaian dosis berdasarkan protokol kemoterapi dan formulir efek samping berdasarkan CTCAE, dengan analisis data secara deskriptif dalam bentuk persentase. Hasil penelitian menunjukkan bahwa seluruh regimen kemoterapi memiliki ketepatan dosis sebesar 100%, dengan efek samping terbanyak berupa rambut rontok (84,3%), diikuti mual dan mudah lelah (68,6%), serta hilang nafsu makan (58,8%), yang umumnya tergolong ringan hingga sedang. Secara keseluruhan, pemberian kemoterapi injeksi kombinasi telah sesuai dengan prinsip keselamatan pasien dan individualisasi terapi.

Referensi

Ali, U., Vungarala, S., & Tiriveedhi, V. (2024). Genomic Features of Homologous Recombination Deficiency in Breast Cancer : Impact on Testing and Immunotherapy. 1–22.

Amelia, K., Rusli, D., & Hikmah, M. (2022a). Evaluasi Penggunaan Obat dan Kesesuaian Dosis Kemoterapi Body Surface Area (BSA) Pasien Kanker Payudara di RSUD Sekayu. Pharmaceutical Journal of Islamic Pharmacy, 6(2), 56. https://doi.org/10.21111/pharmasipha.v6i2.8708

Amelia, K., Rusli, D., & Hikmah, M. (2022b). Evaluasi Penggunaan Obat Dan Kesesuaian Dosis Kemoterapi Body Surface Area (Bsa) Pasien Kanker Payudara Di Rsud Sekayu Evaluation of Drug Use and Appropriate Dose of Chemotherapy Body Surface Area (Bsa) Breast Cancer Patients in Sekayu Hospital. Pharmaceutical Journal of Islamic Pharmacy, 6(2), 56–62.

American Cancer Society. (2016). Understanding a Breast Cancer Diagnosis, Atlanta. Https://Www.Cancer.Org/Cancer/Breast-Cancer/About/Types-of-Breast-Cancer.Html#References, 1–36.

Anjasari1, D., Sumarny2, R., & Wahyudi Uun H. (2018). Evaluasi Penggunaan Obat Dan Kesesuaian Dosis Kemoterapi Body Surface Area ( Bsa ) Pasien Kanker Payudara Di Rsud Sekayu Evaluation Of Drug Use And Appropriate Dose Of Chemotherapy Body. 6(2), 56–62.

Badan POM. (2012). Pedoman Monioring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan. Direktorat Pengawasan Distribusi Produk Terapetik Dan PKRT Badan Pom RI, 1–35.

Belfiglio, M., Fanizza, C., Tinari, N., & Ficorella, C. (2012). Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. 221–229. https://doi.org/10.1007/s00432-011-1091-0

Bhattacharaya. (2016). Relevance of risk factors of breast cancer in women : An Eastern Indian scenario. Urnal Penelitian Dan Terapi Kanker, 12(1). https://doi.org/10.4103/0973-1482.160929

Both, F. (2024). 408 661. 2022, 2024–2025. https://doi.org/10.1002/ijc.33588.

Burnell, M., Levine, M. N., Chapman, J. W., Bramwell, V., Gelmon, K., Walley, B., Vandenberg, T., Chalchal, H., Albain, K. S., Perez, E. A., Rugo, H., Pritchard, K., Brien, P. O., & Shepherd, L. E. (2010). J OURNAL OF C LINICAL O NCOLOGY Cyclophosphamide , Epirubicin , and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. 28(1), 77–82. https://doi.org/10.1200/JCO.2009.22.1077

Cancer, B. (2023). BC Cancer Drug Manual. 2023, 1–3.

Cancer Therapy Evaluation Program (CTEP). (2017). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Therapy Evaluation Program (CTEP), 155. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50

Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-konefka, E., Fallowfield, L. J., Kyriakides, S., Costa, A., Cufer, T., Albain, K. S., & Force, E. T. (2009). International Guidelines for Management of Metastatic Breast Cancer : Combination vs Sequential Single-Agent Chemotherapy. 101(17). https://doi.org/10.1093/jnci/djp235

Cavalcante, F. P., Millen, E. C., & Zerwes, F. P. (2020). Progress in Local Treatment of Breast Cancer : A Narrative Review Evolução do tratamento local do câncer de mama : Revisão narrativa. 356–364.

D, E., Connell, K. O., Ergas, I. J., Valice, E., Roh, J. M., Bhimani, J., Heon, N., Griggs, J. J., Lee, J., Bowles, E. J. A., Donna, R., Kolevska, T., Bandera, E. V, & Kushi, L. H. (2025). Assessment of Breast Cancer Chemotherapy Dose Reduction in an Integrated Healthcare Delivery System. 203(3), 565–574. https://doi.org/10.1007/s10549-023-07126-4.Assessment

Febriani, A., & Pujiastuti, F. (2024). Characteristics of Chemotherapy Treatments for Breast Cancer Patients at Bhayangkara Tk . 1 Pudsdokkes Polri Hospital , Jakarta. 282–288.

Ferlay et al. (2020). Elimination of Cervical Cancer. 2019, 2019–2020.

Ferlay, J., Rebecca, M. E., & Mph, L. S. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. February, 229–263. https://doi.org/10.3322/caac.21834

Formularium Nasional. (2024). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/1818/2024. 1–103.

Gota, V., Nookala, M., Bonda, A., Karanam, A., Shriyan, B., Kembhavi, Y., Gurjar, M., Patil, A., & Singh, A. (2021). Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. January, 3068–3076. https://doi.org/10.1002/cam4.3865

Gurney, H. (2002). How to calculate the dose of chemotherapy. British Journal of Cancer, 86(8), 1297–1302. https://doi.org/10.1038/sj.bjc.6600139

Herawati1, Ka., Rijal2, S., Arsal3, A. S. F., Purnamasari4, R., Abdi5, D. A., & SWahid6, Y. (2021). Fakumi medical journal. 1(1), 44–53.

Huang, L., Wang, X., Zhou, L., Di, L., Zheng, H., Jiang, Z., & Wang, Y. (2020). Oral vinorelbine versus intravenous vinorelbine , in combination with epirubicin as first line chemotherapy in Chinese patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 85(1), 205–215. https://doi.org/10.1007/s00280-019-04000-3

Ira Wulandari. (2023). radioterapi. Jurnal Radiografer Indonesia, 6 no1.

Irawan, M. F., Syahril, E., Chalid, A., & Gunawan, M. I. (2025). Fakumi medical journal. 05(01), 14–21.

Kalli, S., Semine, A., Cohen, S., Naber, S. P., Makim, S. S., & Bahl, M. (2018). American joint committee on cancer’s staging system for breast cancer, eighth edition: What the radiologist needs to know. Radiographics, 38(7), 1921–1933. https://doi.org/10.1148/rg.2018180056

Kemenkes RI. (2022). Profil Kesehatan Indonesia 2021. In Pusdatin.Kemenkes.Go.Id.

Kementerian Kesehatan RI. (2019). Pedoman Nasional Pelayanan Kedokteran: Tata Laksana Kanker Serviks. Kementerian Kesehatan RI, 1–100.

Khan, A., Sisodiya, S., Aftab, M., Tanwar, P., & Hussain, S. (2025). Mechanisms and Therapeutic Strategies for Endocrine Resistance in Breast Cancer : A Comprehensive Review and Meta-Analysis.

Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009). Dose escalation methods in phase i cancer clinical trials. Journal of the National Cancer Institute, 101(10), 708–720. https://doi.org/10.1093/jnci/djp079

Lee, A., & Moon, B. (2014). Chemotherapy in Breast Cancer. 37(2), 75–82.

Lewis, L., Thompson, B., Stellmaker, R., & Koelmeyer, L. (2025). Body composition and chemotherapy toxicities in breast cancer : a systematic review of the literature. Journal of Cancer Survivorship, 914–929. https://doi.org/10.1007/s11764-023-01512-z

Lu, D., Lu, T., Stroh, M., Graham, R. A., Agarwal, P., Musib, L., Li, C. C., Lum, B. L., & Joshi, A. (2016). A survey of new oncology drug approvals in the USA from 2010 to 2015: A focus on optimal dose and related postmarketing activities. Cancer Chemotherapy and Pharmacology, 77(3), 459–476. https://doi.org/10.1007/s00280-015-2931-4

Luo, H., Sun, Y., & Xu, T. (2025). Application status and research progress of targeted therapy drugs for hormone receptor-positive breast cancer. March. https://doi.org/10.3389/fmed.2025.1513836

Maulidia, H. R., Prabamurti, P. N., & Indraswari, R. (2022). Faktor-faktor yang Berhubungan dengan Praktik Pemeriksaan Payudara Sendiri ( SADARI ) dalam Upaya Deteksi Dini Kanker Payudara pada Santriwati Pondok Pesantren di Kecamatan Mijen Kota Semarang Tahun. 162–168.

Mosteller, R. D. (1987). Simplified calculation of body-surface area. In The New England journal of medicine (Vol. 317, Issue 17, p. 1098). https://doi.org/10.1056/NEJM198710223171717

(NCCN), N. C. C. N. (2023). DRUG NAME : Fluorouracil. June, 1–14.

Nindrea, R. D., Aryandono, T., & Lazuardi, L. (2017). Breast Cancer Risk From Modifiable and Non-Modifiable Risk Factors among Women in Southeast Asia : A Meta-Analysis. 18, 3201–3206. https://doi.org/10.22034/APJCP.2017.18.12.3201

Noman, S., Shahar, H. K., Rahman, H. A., Ismail, S., Al-jaberi, M. A., & Azzani, M. (2021). The Effectiveness of Educational Interventions on Breast Cancer Screening Uptake , Knowledge , and Beliefs among Women : A Systematic Review.

Nurlaili, H., Fitri, N., & Pertiwi, A. (2024). Pelatihan SADARI pada Remaja Perempuan sebagai Upaya Peningkatan Pemahaman Deteksi Dini Kanker Payudara. 2(9), 4134–4139.

Petrovi, D. (2025). Comparative Diagnostic Efficacy of Four Breast Imaging Modalities in Dense Breasts : A Single-Center Retrospective Study.

Prof Dr. sugiyono. (2019). Metoda Penelitian Kuantitatif Kualitatif Dan R&D.

Qari, A. S., Mowais, A. H., Ahmed, A., Asiri, A., Alwatid, S. A., Alharbi, S. M., Almuayrifi, M. J., Aljohani, A. A., Alanazi, R. M., & Thoubaity, F. Al. (2024). Adjuvant and Neoadjuvant Therapy for Breast Cancer : A Systematic Review. 20(3), 156–166. https://doi.org/10.4274/ejbh.galenos.2024.2023-12-16

Rosya, E., & Kusumadewi, A. I. (2019). Pengetahuan Tentang Kanker Payudara Berhubungan Dengan Perilaku Pemeriksaan Payudara Secara Klinis.

S Bartolini, L. C. and P. C. (2004). Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. 31–35. https://doi.org/10.1038/sj.bjc.6601518

Sari, N. W., Soekarno, J., No, H., Ganting, M., Mandiangin, K., & Selayan, K. (2019). Karakteristik Kejadian Kanker Payudara Di RSUD Dr . Achmad Mochtar Kota Bukittinggi. 2(2), 73–82.

Sharma D, S. G. (2017). Male Breast Cancer: An Overview. 98–102. https://doi.org/10.4103/jrcr.jrcr

Smolarz, B., Zadro, A., & Romanowicz, H. (2022). Treatment ( Review of Literature ). 1–27.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 71(3), 209–249. https://doi.org/10.3322/caac.21660

Syamsuddin. (2025). Faktor-Faktor Yang Berhubungan Dengan Kejadian Ca Mamae Di Rsud Provinsi Gorontalo. 10(1).

Tomasello, G., Gambini, D., Petrelli, F., Azzollini, J., Arcanà, C., Ghidini, M., Peissel, B., Manoukian, S., & Garrone, O. (2022). Characterization of the HER2 status in BRCA- mutated breast cancer : a single institutional series and systematic review with pooled analysis. ESMO Open, 7(4), 100531. https://doi.org/10.1016/j.esmoop.2022.100531

Wang, B., Sun, T., Zhao, Y., Wang, S., Zhang, J., Wang, Z., Teng, Y., Cai, L., Yan, M., Wang, X., Jiang, Z., Pan, Y., Luo, J., Shao, Z., & Wu, J. (2022). A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. https://doi.org/10.1038/s41467-022-31704-7

Wang, Z. H. I., Dang, C., Zhu, K. U. N., Zhang, Y., Chang, D., Xia, P., Song, Y., & Li, K. (2015). Cyclophosphamide , epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients. 1088–1092. https://doi.org/10.3892/mco.2015.584

Wickramasinghe, V., Sathyadas, G., & Lamabadusuriya, S. P. (2009). Body surface area estimation: Cross validation of several prediction equations. Sri Lanka Journal of Child Health, 38(2), 54. https://doi.org/10.4038/sljch.v38i2.679

Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L., Huang, L., Liu, C., & Shao, Z. (2025). Breast cancer : pathogenesis and treatments. December 2024. https://doi.org/10.1038/s41392-024-02108-4

Xu, L. B., Smith, E. R., Koutouratsas, V., & Chen, Z. (2025). The Persistent Power of the Taxane / Platin Chemotherapy. 1–13.

Yuliana. (2019). Literature Review : Perkembangan Pengobatan Kemoterapi Kanker Payudara. Makassar Pharmaceutical Science Journal, 2024(2), 2024–2056.

Zhang, W., Wang, Q., Jiang, D., Xu, X., Zheng, X., & Qiu, M. (2021). A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. 1–15.

Zhou, L., Xu, S., Yin, W., Lin, Y., Du, Y., & Jiang, Y. (2017). Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer : a prospective , single arm , phase II study. 8(45), 79305–79314.